The company got some bad news to start 2026.

Healthcare, retail and finance stocks could do well in 2026. See five picks that experts say could have major upside ...

Pfizer Inc. (NYSE:PFE) is included among Dividend Contenders List: Top 20 Stocks. Reuters reported on January 20 that Britain ...

A case in point is the dire need for new antimicrobials, but pharmaceutical companies have little financial incentive to ...

Discover tailored retirement income strategies. Learn our Income Method and two resilient, cash-generating solutions for ...

We came across a bullish thesis on The Cigna Group on The Passive Income Portfolio’s Substack. In this article, we will ...

Regeneron Pharmaceuticals, Inc. nears a key earnings report after a strong JPM Healthcare update. Click here to find out why ...

Astellas' CEO said he doesn't want to make acquisitions simply to fill a revenue gap. Takeda is preparing for Trintellix's U.S. patent expiry with a round of layoffs. | Astellas CEO said he doesn't ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.

Both companies may succeed in this industry.

Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.

LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens ...